Table 2.
Maximum grade acute and late adverse effect after treatment in 56 evaluable patients.
| Acute Toxicity | Late Toxicity | |||||
|---|---|---|---|---|---|---|
| G1 | G2 | G3 | G1 | G2 | G3 | |
| General Symptoms | ||||||
| Hypertension | 10 (17.86%) | 26 (46.43%) | 19 (33.93%) | 18 (45.0%) | 17 (42.50%) | 5 (12.50%) |
| Asthenia | 18 (32.14%) | 3 (5.36%) | 2 (3.57%) | |||
| AST/ALT elevation | 11 (19.64%) | |||||
| Somnolence/Insomnia | 5 (8.93%) | 3 (5.36%) | ||||
| Headache/loss of concentration | 1 (1.79%) | 1 (1.79%) | 1 (1.79%) | |||
| Dizzines/ortostasim | 6 (10.71%) | 1 (1.79%) | 1 (1.79%) | 1 (1.79%) | ||
| Depression/Anxiety | 1 (1.79%) | 1 (1.79%) | 3 (5.36%) | |||
| Dry skin | 3 (5.36%) | 1 (1.79%) | 2 (3.57%) | |||
| Skin hyperpigmentation folliculitis | 2 (3.57%) | 1 (1.79%) | ||||
| Mialgia/leg discomfort | 3 (5.36%) | |||||
| Arthralgia | 3 (5.36%) | 1 (1.79%) | ||||
| Symptoms related to hormonal changes | ||||||
| Breast Pain | 14 (25.00%) | 3 (5.36%) | 11 (19.64%) | |||
| Nipple pain/discomfort | 3 (5.36%) | 1 (1.79%) | ||||
| Gynecomastia | 13 (23.21%) | 5 (8.93%) | 8 (14.29%) | |||
| Hot flashes | 2 (3.57%) | 1 (1.79%) | ||||
| Libido Decreased | 7 (12.50%) | 6 (10.71%) | ||||
| Retrograde ejaculation | 2 (3.57%) | 2 (3.57%) | ||||
| Hipogonadism | 2 (3.57%) | 1 (1.79%) | ||||
| Urinary symptoms | ||||||
| Pain | 12 (21.43%) | 6 (10.71%) | 1 (1.79%) | 1 (1.79%) | ||
| Urgency | 13 (23.21%) | 6 (10.71%) | 3 (5.36%) | 1 (1.79%) | ||
| Incontinence | 9 (16.07%) | 1 (1.79%) | ||||
| Polaquiuria | 4 (7.14%) | 8 (14.81) | 2 (3.57%) | |||
| Retention/obstruction | 2 (3.57%) | 4 (7.14%) | 1 (1.79%) | 1 (1.79%) | ||
| Non infectous cystitis | 4 (7.14%) | 1 (1.79%) | ||||
| Nicturia | 1 (1.79%) | |||||
| Gastrointestinal Symptoms | ||||||
| Abdominal Pain | 4 (7.14%) | 2 (3.57%) | ||||
| Rectal Pain | 4 (7.14%) | 1 (1.79%) | 1 (1.79%) | |||
| Proctitis | 7 (12.50%) | 2 (3.57%) | 1 (1.79%) | |||
| Anorexia/Hyporexia | 5 (8.93%) | 1 (1.79%) | 1 (1.79%) | |||
| Disgeusia | 2 (3.57%) | 1 (1.79%) | ||||
| Constipation/Diarrhea | 8 (14.29%) | |||||
| Nausea/Vomitting | 5 (8.93%) | 1 (1.79%) | ||||
| Meteorism | 2 (3.57%) | |||||
Acute grade 4 was observed in 2 patients (one hypertensive crisis and one elevation of AST/ALT). No grade 4 late toxicity was observed.